BRCA1/2 Mutations and bevacizumab in the neoadjuvant treatment of breast cancer: Response and prognosis results in patients with triple-negative breast cancer From the geparquinto study

Peter A. Fasching, Sibylle Loibl, Chunling Hu, Steven N. Hart, Hermela Shimelis, Raymond Moore, Christian Schem, Hans Tesch, Michael Untch, Jörn Hilfrich, Mahdi Rezai, Bernd Gerber, Serban Dan Costa, Jens Uwe Blohmer, Tanja Fehm, Jens Huober, Cornelia Liedtke, Richard M. Weinshilboum, Liewei Wang, James N. IngleVolkmar Müller, Valentina Nekljudova, Karsten E. Weber, Brigitte Rack, Matthias Rübner, Gunter Von Minckwitz, Fergus J. Couch

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Fingerprint

Dive into the research topics of 'BRCA1/2 Mutations and bevacizumab in the neoadjuvant treatment of breast cancer: Response and prognosis results in patients with triple-negative breast cancer From the geparquinto study'. Together they form a unique fingerprint.

Medicine & Life Sciences